Growing Interest in BioPartnering Europe from Big Pharma; 26% Increase in Delegates from Large Pharmaceutical Companies
Latest figures on registrants for the 12th Annual BioPartnering Europe (BPE) conference reveal that there is growing interest in the event from large pharmaceutical companies. Compared with last year, pharma company registrations have increased by 26%.
BioPartnering Europe offers pharmaceutical companies the ideal networking environment for the creation of new partnerships, alliances and licensing deals with start-up and established biotech companies — as well as promoting dialogue with financial and other services companies.
Robin Breckenridge, Vice President, Head of Operations and Informatics, Roche Pharma Partnering, commented: “Roche regards BPE as a valuable opportunity to meet face to face with key figures in the biotech industry. We look forward to speaking about our latest activities in the partnering arena and to hearing about the current needs and views of biotech companies.”
This popular event offers pharma companies the opportunity to explain their evolving partnering strategies to companies, allows them to introduce ways of accessing deals and partnering/licensing opportunities, and provides an ideal platform with which to present a clear picture of their company’s wish-list of products and technologies for the coming year.
The Open House and Emerging Company presentations are two of the hallmarks of BPE. The early sellout of all available presenting slots reflects their continued popularity. Applications are still being accepted for companies wishing to be added to the waiting list for presentation slots.
BioVex Limited, a U.K.-based biotech company took part in last year’s Open House presentations and they are returning to BPE again this year. Dr. Tony Mills, Director of Business Development, BioVex, commented, “We’re attending BPE because, quite simply, Technology Vision Group puts on the best biopartnering meetings and we want to be there to see and be seen.”
Full conference details are available online at: http://www.techvision.com/bpe .
A complete list of registered presenters can be viewed below and at the following link: http://www.techvision.com/bpe/presenters.php .
Registered Pharma Companies:
3M Health Care, Almirall, Amgen, AstraZeneca, Aventis Pharma Deutschland GmbH, Barrier Therapeutics, Inc., BioWa, Inc./Kyowa Pharmaceutical, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cambridge Laboratories Ltd, Celltech plc, Chiesi Farmaceutici Spa, Chugai Pharma Europe Ltd, CoTherix, Inc., Eli Lilly & Company Ltd., Elpen S.A., F. Hoffmann-La Roche Ltd., Faes Farma S.A., Forest Laboratories, Inc., Genentech, Inc., Genesis Pharma SA, Genzyme Corporation, GlaxoSmithKline plc, ICOS Corporation, Jazz Pharmaceuticals, Inc., Johnson & Johnson, Menarini Group, Merck & Co. Inc., Novartis Pharmaceuticals, Pfizer Ltd, QLT Inc., SCC (Sosei Consulting Corporation), Schering AG, Schwarz BioSciences, Serono, Shire Pharmaceuticals Group plc, Somaxon Pharmaceuticals, UCB S.A., and Wyeth.
Emerging Company Presenters:
Alexza, Alligator Bioscience, Allon Therapeutics, Aptanomics, Austrianova Biotechnology, BioXell SpA, CareX SA, Cilian AG, Cryptome Pharmaceuticals Ltd, CrystalGenomics, Inc., Cygenics, Faust Pharmaceuticals, Ionix Pharmaceuticals, Lectus Therapeutics Ltd, Molecular Skincare Ltd., Mosaic Systems BV, NANO-S Biotechnology, Nuevolution A/S, PIramed Ltd., Sirenade Pharmaceuticals AG, Somaxon Pharmaceuticals, Synexa Life Sciences, Thios Pharmaceuticals, and U3 Pharma AG.
Open House Presenters:
ACE BioSciences, Acrux Ltd, Affymax, Inc., Agensys, Inc., Ambit Biosciences, Antisoma Plc, Aponetics AG, Arakis Limited, Argenta Discovery Ltd, Ark Therapeutics, Arrow Therapeutics Ltd, ARYx Therapeutics, Astex Technology Limited, atugen AG, Avecia Biotechnology, AVI BioPharma Inc, Avidex Ltd, Barrier Therapeutics, Inc., BioInvent, Biolex, Biolipox AB, BioRexis Pharmaceutical Corporation, Biota, BioVex Ltd, BioVisioN AG, BioWa, Inc., BTG plc, Celator Technologies Inc., Cell Genesys, Inc., Chromos Molecular Systems, Cobra BioManufacturing Plc, CombinatoRx, Corgentech, Inc., Cyclacel Ltd, Cytokinetics, Inc., De Novo Pharmaceuticals Ltd, EGeen International, Endocube, Epigenomics AG, Evotec OAI, ExonHit Therapeutics, Gala Biotech/Cardinal Health, Galapagos Genomics, Gene Bridges GmbH, Global Genomics AB, GPC Biotech AG, Graffinity Pharmaceuticals, Health Protection Agency, Hybridon, Inc., Inex Pharmaceuticals Corporation, Inflazyme Pharmaceuticals, Ingenium Pharmaceuticals AG, Inimex Pharmaceuticals Inc., Inpharmatica Ltd, Intronn, Inc., Ipsat Therapies Ltd., JERINI AG, Lorantis Ltd, Lorus Therapeutics Inc., MaxCyte, Inc., Maxim Pharmaceuticals, MDS Pharma Services, Medicago Inc., MediciNova, Inc., MedPharm Ltd, Microscience Ltd, ML Laboratories plc, MorphoSys AG, Morphotek, Inc., Myogen, Inc., Nautilus Biotech, Neuro3d, Novozymes A/S, OctoPlus, OncoGenex Technologies Inc., Oncolytics Biotech Inc., OptiNose AS, Oxford BioMedica Plc, Paradigm Therapeutics Ltd, ProPharma Limited, Proteome Sciences plc, PTC Therapeutics, Inc., Sangamo Biosciences, Serologicals Corporation, Sidec Technologies AB, Stressgen Biotechnologies Corp., Syngenta AG, TargeGen, Inc., TopoTarget UK Ltd, Transgene S.A., Transition Therapeutics Inc., Trigen Ltd, Twinstrand Therapeutics Inc., Umedik Inc., Valentis, Inc., Xantos Biomedicine AG, Xencor, Xenova Group Ltd, YM BioSciences Inc., and Zygogen.
Conference Sponsors:
Amgen, Apax Partners Ltd, AstraZeneca, Aventis Pharma Deutschland GmbH, BioCentury, BIOQuebec, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Burrill & Company, Business Wire, Clearview Projects, Inc., Cooley Godward LLP, Deloitte & Touche LLP, Dresdner Kleinwort Wasserstein, Eli Lilly and Company, Enterprise Ireland, Ferghana Partners Group, Genentech, Inc., Genzyme Corporation, GlaxoSmithKline plc, De Facto Communications plc, Johnson & Johnson, Merck & Co., Inc., Metro Atlanta Bioscience Council, Nature Biotechnology, Novartis, Palmer & Dodge LLP, R.J. Watkins & Company, Roche, Schering AG, Taylor Wessing and Welsh Development Agency – Bioscience Unit.
Conference Supporters:
ACET, BC Biotech, BIA, Global Bioscience Partnership, UK Trade & Investment, and US Commercial Service.
